$STRW

Strawberry Fields REIT (STRW) director adds 392 shares in open-market buy

Strawberry Fields REIT director Gertz Stanford purchased 392 shares of Common Stock in an open-market transaction at $12.89 per share, increasing his direct holdings to 819 shares. This Form 4 filing indicates a neutral sentiment, reflecting a modest increase in his personal stake. The transaction details and his total holdings are publicly disclosed.

Original reporting
Published Apr 1, 2026, 7:39 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Apr 1, 2026, 8:01 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$STRW
Bullish
medium confidence
Mentioned
$STRW
Relevance
6/10
AlphAI data visualization · based on Stock Titan
Decision brief

The 30-second read

$STRWBullishMed
01

Why it matters

The insider purchase may positively influence investor sentiment, potentially leading to short-term price appreciation.

02

Market read

The news has moderate relevance to traders focusing on REITs and insider activity signals.

03

What to watch

Market-wide conditions and company fundamentals should be analyzed to validate the implied optimism.

Relevance 6/10Timing: Immediate, as the transaction was recent.

Background

Strawberry Fields REIT is involved in real estate investments, with recent insider activity highlighting increased insider confidence.

Company-level read

Ticker impact

$STRWBullishMedium confidence
Context

The insider purchase by Strawberry Fields REIT's director indicates a potential positive outlook for the company's stock.

Expected impact

Moderate upward price movement expected in the short to medium term.

Evidence & confidence

Insider buying often reflects positive internal outlook; however, the modest size of the purchase and overall neutral sentiment suggest caution.

Market effects

Potential positive sentiment in the real estate investment trust sector.

Limited, as the news pertains to a specific company's insider activity.

Negligible, as this is a company-specific event.

Counterpoint

The insider purchase is modest and could be routine; it does not necessarily indicate a significant positive shift.

Key entities

  • Gertz Stanford

    Director of Strawberry Fields REIT who made the recent purchase.

  • Strawberry Fields REIT (STRW)

    Real estate investment trust involved in the transaction.

Related articles

$STRWMed

Strawberry Fields REIT CEO Maps SNF Growth Strategy, 100% Rent Collection Record

Strawberry Fields REIT CEO highlighted growth strategy, 100% rent collection, and operator financial health. The company focuses on skilled nursing facilities, benefiting from aging demographics and regulatory barriers. It closed a $200M credit line, has low leverage, and trades at a discount to peers due to limited liquidity. The company generates $74M in AFFO, with a 10.5x AFFO valuation.

$STRWMed

Strawberry Fields REIT (STRW) Q2 2026 Earnings Call Transcript

Strawberry Fields REIT (STRW) held its Q2 2026 earnings call. For the first six months of 2026, revenue rose to $80 million (+6.4%) and net income was $18.4 million. AFFO was $73.9 million, with projected 10.1% AFFO growth per share in 2026. The company reported 100% rent collection, $300 million credit facility, and a $0.17 Q3 dividend.

$STRWMed

Strawberry Fields REIT Q2 Earnings Call Highlights

Strawberry Fields REIT (STRW) reported Q2 adjusted funds from operations (AFFO) of $73.9 million and projected 10.1% AFFO-per-share growth. It posted adjusted EBITDA of $135.7 million, 14.4% lease yield, and net debt to net assets of 49.8%. The board approved a $0.17 quarterly dividend. The company closed a $300 million credit facility and contracted to buy a Missouri hospital campus for $10.4 million.

$CLYMHighAI 8/10

Climb Bio reports early data on budoprutug for kidney diseases

Climb Bio (CLYM) presented Phase 2 trial data for budoprutug, an anti-CD19 antibody, showing B-cell depletion and PLA2R antibody reductions in kidney disease patients. The 200 mg dose achieved 70% mean antibody reduction, with 5/13 patients in remission. The 600 mg dose showed deeper B-cell depletion. The drug was well-tolerated. Climb Bio expects more data in 2027. Primary membranous nephropathy affects 75,000 people in the U.S. without FDA-approved treatments.